Article Text

other Versions

Download PDFPDF
New horizons for platinum-resistant ovarian cancer: insights from the 2023 American Society of Clinical Oncology (ASCO) and European Society for Medical Oncology (ESMO) Annual Meetings
  1. Khalid El Bairi1,2,
  2. Ainhoa Madariaga3,
  3. Dario Trapani4,5,
  4. Ouissam Al Jarroudi1,6 and
  5. Said Afqir1,6
  1. 1Department of Medical Oncology, Mohammed VI University Hospital, Oujda, Morocco
  2. 2Faculty of Medical Sciences, University Mohammed 6 Polytechnic, Ben Guerir, Morocco
  3. 3Department of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain
  4. 4European Institute of Oncology, IRCCS, Milan, Italy
  5. 5Department of Oncology and Hematology, University of Milan, Milan, Italy
  6. 6Faculty of Medicine and Pharmacy, Mohammed Ist University, Oujda, Morocco
  1. Correspondence to Mr Khalid El Bairi, Faculty of Medical Sciences, University Mohammed 6 Polytechnic, Ben Guerir, Morocco; k.elbairi{at}


Platinum-resistant ovarian cancer is difficult to treat and has a poor prognosis. Patients with platinum-resistant ovarian cancer have limited treatment options and often have a limited benefit from existing chemotherapeutic agents. There is a lack of contemporary effective anticancer drugs and reliable predictive biomarkers for this aggressive cancer. Recent cutting-edge research presented at the 2023 American Society of Clinical Oncology (ASCO) and the European Society for Medical Oncology (ESMO) Annual Meetings has provided insights into several potential therapeutic targets, such as DNA damage repair proteins, cell-cycle regulators, and immune-modulating agents. In addition, antibody–drug conjugates have provided new practice-changing results in platinum-resistant ovarian cancer. Here, we review the results of research presented at this annual event, with a focus on clinical trials investigating novel treatment approaches for platinum-resistant ovarian cancer, in addition to predictive and prognostic biomarkers for optimal patient selection, and other topics, such as real-world evidence.

  • ovarian cancer

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Twitter @elbairikhalid19, @AinhoaMada

  • Correction notice This article has been corrected since it was first published. An inaccurate study completion date has been removed.

  • Contributors KE wrote the manuscript. AM, DT reviewed the manuscript. OA and SA supervised the review writing. All authors approved the final version of the manuscript.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests KE reports receiving fees and honoraria from NCODA, Techspert, Elsevier and Springer and funding from the Cancer Research Institute (Morocco). DT, SA, and OA: nothing to report. AM: reports honoraria from AstraZeneca, GSK, MSD, PharmaMar.

  • Provenance and peer review Not commissioned; externally peer reviewed.